Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.

David S HongNicole ConcinIgnace VergoteJohann S de BonoBrian M SlomovitzYvette DrewHendrik-Tobias ArkenauJean-Pascal MachielsJames F SpicerRobert JonesMartin D ForsterNathalie CornezChristine GennigensMelissa L JohnsonFiona C ThistlethwaiteReshma A RangwalaSrinivas GhattaKristian WindfeldJeffrey R HarrisUlrik Niels LassenRobert L Coleman

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Tisotumab vedotin demonstrated a manageable safety profile and encouraging antitumor activity in patients with previously treated recurrent or metastatic cervical cancer.

Keyphrases

squamous cell carcinoma
small cell lung cancer
hodgkin lymphoma
newly diagnosed